NCT05300997Recruiting
Translational Immunodiagnostics in Stroke (TrImS)
Translational Immunodiagnostics in Suspected Stroke (TrImS): A Two-centre, Pragmatic, Prospective, Observational Study
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim: 1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 2. to identify early brain- and pathology-specific, panorOmic biomarkers in saliva that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 3. to derive biomarker platforms of models for early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis 4. to validate these models in independent and external datasets
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 650 (estimated)
- First submitted
- 25 Feb 2022
- Start date
- 1 May 2022
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- The University of Hong Kong
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT05300997
What you commit to
- Study type: Observational
- Planned participants: 650
- From 1 May 2022 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Clear onset of acute symptoms \>24 hours.
Who the study is looking for
- Patients eligible for enrolment include:
- Adults ≥18 years of age.
- Suspected acute stroke. Defined as either FAST-positive, or LAPSS-positive or ROSIER\>0
- Within 24 hours of symptom onset.
- Informed consent.
- Control subjects will be drawn from two groups:
- Non-neurologic patients who are matched with TIA and stroke cases (AIS, HS) for age, race, gender and smoking plus one or more of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidaemia.
- Relatives or accompanying friends.
- Note that we will include and collect samples from the following cases if they present as suspected stroke and are recruited \<24 hours from symptom onset.
- Any central nervous system infection, i.e. meningitis or encephalitis in the past 30 days
- Any form of head trauma, stroke or intracranial haemorrhage in the past 30 days
- Known primary or metastatic cancer involving the brain
- Active cancer is defined as a diagnosis of cancer, within 6 months before enrollment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer.
- Autoimmune diseases: such as lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis
- Active infectious diseases (e.g. HIV/AIDS, hepatitis C)
- Major surgery within three months prior to the index event
Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hong Kong University Coordinator of this site? Confirm its status | Hong Kong | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.